Holen Sie sich die Stockscreener-App
12.05
0.08%
-0.010
Handel nachbörslich:
12.05
Schlusskurs vom Vortag:
$12.06
Offen:
$12.03
24-Stunden-Volumen:
642.38K
Relative Volume:
0.89
Marktkapitalisierung:
$4.33B
Einnahmen:
$4.79B
Nettoeinkommen (Verlust:
$-317.00M
KGV:
-13.24
EPS:
-0.91
Netto-Cashflow:
$-59.00M
1W Leistung:
-1.63%
1M Leistung:
-22.56%
6M Leistung:
-41.73%
1J Leistung:
-17.69%
1-Tages-Spanne:
$11.81
$12.17
1-Wochen-Bereich:
$11.62
$12.38
52-Wochen-Spanne:
$10.46
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
12.05 | 4.33B | 4.79B | -317.00M | -59.00M | -0.91 |
|
ISRG
Intuitive Surgical Inc
|
468.32 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
196.61 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
91.38 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
210.87 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
78.70 | 15.83B | 3.90B | 392.30M | 288.10M | 1.95 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Fitch upgrades Bausch + Lomb rating, maintains evolving watch - Investing.com
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg.com
Bausch & Lomb Corp (BLCO) Shares Down 3.1% on Apr 15 - GuruFocus
Bausch & Lomb Agrees to End Vitamin-Patent Suit Ahead of Trial - Bloomberg Law News
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? - Yahoo
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & SuppliesSpecialty Segment - Yahoo Finance
Bausch + Lomb Gears Up For Q1 2025 Results Announcement - Finimize
RBC Capital cuts Bausch & Lomb price target to $17, maintains Outperform - Investing.com
Stifel cuts Bausch & Lomb stock target to $15, maintains hold - Investing.com UK
Lawyers focus on Bausch + Lomb recall investigation | 2025-03-31 | Investing News - Stockhouse
Bausch & Lomb Patents’ Validity Should Go to Trial, Judge Says - Bloomberg Law News
WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty - Baystreet.ca
Wells Fargo cuts Bausch & Lomb stock rating, lowers target to $15 - Investing.com UK
Bausch + Lomb recalls some of its implantable eye lenses - Reuters
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb shares fall on voluntary recall By Investing.com - Investing.com India
Bausch + Lomb to Announce Q1 2025 Financial Results - TipRanks
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30 - Yahoo Finance
Bausch & Lomb Says Amcor Must Pay For Botched Bottles - Law360
Bausch + Lomb credit rating upgraded to ’B’ at S&P, parent company outlook developing - Investing.com India
Jury Should Hear Bausch & Lomb Vitamin-Patent Claims, Judge Says - Bloomberg Law News
Stocks In Play: Bausch + Lomb Corporation - Barchart
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States - BioSpace
Contact Lenses Market Forecast Report and Company Analysis 2025-2033 Featuring Bausch & Lomb, Alcon, Carl Zeiss Meditec, The Cooper Companies, Hoya, EssilorLuxottica, Menicon, and Seed - Yahoo Finance
U.S. Contact Lenses Market Size and Share Analysis 2025-2033, Featuring Bausch & Lomb, Alcon, Carl Zeiss Meditec, The Cooper Companies, Hoya Corporation & More - Yahoo Finance
Judge Advises Affirming Bausch & Lomb Vitamin Patents' Validity - Bloomberg Law News
Bausch + Lomb's SWOT analysis: eye health stock sees growth amid challenges - Investing.com
Morgan Stanley cuts Bausch & Lomb stock target to $18 from $19 - Investing.com
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts - Defense World
Bank of America Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $17.00 - Defense World
Bausch & Lomb stock target cut to $20 at H.C. Wainwright - Investing.com UK
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2024 Earnings Call Transcript - Insider Monkey
Bausch & Lomb Begins to Reap Fruits of Innovation; Broad-Based Growth Fuels Our Long-Term Outlook - Morningstar
Bausch + Lomb Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance - BioSpace
Bausch + Lomb Corp. Announces FY25 Revenue Within View - Nasdaq
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results - TradingView
Bausch + Lomb Posts Q4 Revenue of US$1.28 Billion -February 19, 2025 at 06:59 am EST - Marketscreener.com
Bausch + Lomb shares surge over 4% on earnings beat and strong outlook - Investing.com
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Increases By 37.3% - MarketBeat
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Unlocking Q4 Potential of Bausch + Lomb (BLCO): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Bausch + Lomb Sinks After Disclosing It Won’t Go Private Now - Bloomberg
Contact lens maker Bausch + Lomb rules out going private at this time - Reuters
Bausch + Lomb sinks after disclosing it won’t go private now - The Malaysian Reserve
Contact lens maker Bausch + Lomb rules out take-private deal - Yahoo Canada Finance
Bausch + Lomb Provides Update on Potential Sale - Business Wire
Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Target Price at $20.25 - MarketBeat
Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch + Lomb, RBC Says - Marketscreener.com
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.50%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):